Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 1 Study of E7389 Liposomal Formulation in Solid Tumors
jRCT2080223593Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eribulin in Nonhematologic neoplasms, breast cancer, triple-negative breast cancer (TNBC) and 4 more, sponsored by Eisai Co., Ltd. Started Jul 2017; status: completed.
02
Drugs
eribulin
03
Conditions
Nonhematologic neoplasmsbreast cancertriple-negative breast cancer (TNBC)adenoid cystic carcinoma (ACC)gastric cancer (GC)
Beyond the preview
Go deeper on jRCT2080223593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223593.